A phase II trial of MCB 3837 for the treatment of Clostridium difficile infection
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2016
At a glance
- Drugs MCB 3837 (Primary)
- Indications Clostridium infections
- Focus Proof of concept; Therapeutic Use
- 28 Jun 2016 New trial record
- 22 Jun 2016 According to a Morphochem Inc. media release, the US FDA has accepted IND application for MCB 3837 intended to treat Clostridium difficile infection.
- 22 Jun 2016 This trial is expected to initiate in the second half of 216, according to a Morphochem Inc. media release.